Safety and tolerability of targeted therapies for pulmonary hypertension in children

Pediatric Cardiology

Volumn 35, Issue 3, 2014, Pages 490-498

  Roldan, T ^a   Deiros, L ^a   Romero, J A ^a   Gutierrez Larraya, F ^a   Herrero, A ^a   Del Cerro, M J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Pediatrics; Pharmacotherapy; Pulmonary hypertension; Safety

Indexed keywords

AMBRISENTAN; BOSENTAN; DOMPERIDONE; ILOPROST; PARACETAMOL; PROSTACYCLIN; RANITIDINE; SALBUTAMOL; SILDENAFIL; SITAXSENTAN; TREPROSTINIL;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLEEDING TENDENCY; BODY WEIGHT; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EMOTIONAL DISORDER; EPISTAXIS; ERECTILE DYSFUNCTION; EYE DISEASE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEMATOMA; HOSPITAL ADMISSION; HOSPITALIZED CHILD; HOT FLUSH; HUMAN; HYPOTENSION; INCIDENCE; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JAW PAIN; LIMB PAIN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL IRRITATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NOSE OBSTRUCTION; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; TREATMENT WITHDRAWAL; TREMOR; VISUAL DISORDER; VOMITING;

ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; LONGITUDINAL STUDIES; MALE; PIPERAZINES; PURINES; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84897595650     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-013-0811-4     Document Type: Article

References (26)

1. Armas H, Ortigosa L (2008) Reflujo gastroesofágico y esofagitis en niños. In: SEGHNP (ed) Tratamiento en gastroenterología, hepatología y nutrición pediátrica. Ergon, Madrid, pp 92-94
2. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28(6):1195-1203
3. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S78-S84
4. Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD (2012) Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 125(1):113-122
5. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL (2012) A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125(2):324-334
6. Barst RJ, Layton Jr, Konourina I, Richardson H, Beguetti M, Ivy DD (2012) Starts-2: Long term survival with oral sildenafil monotherapy in treatment-naive patients with pediatric pulmonary arterial hypertension. Abstract presented at the European Society of Cardiology meeting, Munich, 25-29 August 2012
7. Beghetti M, Hoeper MM, Kiely DG, Carlsen J, Schwierin B, Segal ES, Humbert M (2008) Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European postmarketing surveillance program. Pediatr Res 64(2):200-204
8. Berger RM, Bonnet D (2010) Treatment options for paediatric pulmonary arterial hypertension. Eur Respir Rev 19(118):321-330
9. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ (2012) Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 379(9815):537-546
10. Del Cerro MJ, Abman S, Díaz G, Freudenthal S, Freudenthal F, Harikrishnan S, Haworth SG, Ivy D, Lopes AA, Raj JU, Sandoval J, Stenmark K, Adatia I (2011) A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ 1(2):286-299
11. Flolan® (2012) Summary of product characteristics. GlaxoSmithKline, Durban
12. Haworth SG, Hislop AA (2009) Treatment and survival in children with pulmonary arterial hypertension: the UK pulmonary hypertension service for children 2001-2006. Heart 95(4):312-317
13. He B, Zhang F, Li X, Tang C, Lin G, Du J, Jin H (2010) Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74(7):1458-1464
14. Hershey AD (2005) What is the impact, prevalence, disability, and quality of life of pediatric headache? Curr Pain Headache Rep 9:34-344
15. Kim HS, Conklin JL, Park H (2006) The effect of sildenafil on segmental oesophageal motility and gastro-oesophageal reflux. Aliment Pharmacol Ther 24(7):1029-1036
16. Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, Bonnet D (2011) Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 158(4):584-588
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239-245
18. Oishi P, Datar SA, Fineman JR (2011) Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. Expert Opin Pharmacother 12(12):1845-1864
19. Remodulin® (2011) Label Information. United Therapeutics Corporation, New York
20. Revatio® (2010) Summary of product characteristics. Pfizer Limited, Mumbai
21. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1 Suppl):S43-S54
22. Thelin® (2006) Summary of product characteristics. Pfizer Limited, Mumbai
23. Tracleer® (2007) Summary of product characteristics. Actelion Registration Ltd
24. van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JL, Rammeloo L, Clur SA, Mulder BJ, Berger RM (2011) Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 124(16):1755-1764
25. Ventavis® (2008) Summary of product characteristics. Bayer Pharma AG, Leverkusen
26. Volibris® (2008) Summary of product characteristics. Glaxo Group Ltd, Middlesex